Douglas J Sheffler

USPTO Granted Patents = 9 (Patent Applications = 2)

CIPO Patents = 1 (Patent Applications = 2)

EPO Patents = 2

Average Co-Inventor Count = 4.4

ph-index = 2

Forward Citations = 7(Granted Patents)

Location History:

La Jolla, CA (US) (2018 - 2020)
San Diego, CA (US) (2022)

Company Filing History:

7 out of 90

Sanford Burnham Prebys Medical Discovery Institute

patents

3 out of 577

The Salk Institute for Biological Studies

Sanford-Burnham Medical Research Institute

where one patent can have more than one assignee

Years Active: 2018-2025

Loading Chart...

9 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12465594 - Compositions and methods for the modulation of the corticotropin releasing factor binding protein and the treatment of alcohol use disorder (2025-11-11),

2. 11447453 - Metabotropic glutamate receptor negative allosteric modulators (NAMs) and uses thereof (2022-09-20),

3. 10774092 - ULK1 inhibitors and methods using same (2020-09-15),

4. 10689397 - ULK1 inhibitors and methods using same (2020-06-23),

5. 10597367 - Metabotropic glutamate receptor negative allosteric modulators (NAMs) and uses thereof (2020-03-24),

6. 10377695 - Metabotropic glutamate receptor positive allosteric modulators (PAMS) and uses thereof (2019-08-13),

7. 10266549 - ULK1 inhibitors and methods using same (2019-04-23),

8. 10099993 - Metabotropic glutamate receptor positive allosteric modulators (PAMS) and uses thereof (2018-10-16),

9. 9969726 - Metabotropic glutamate receptor negative allosteric modulators (NAMS) and uses thereof (2018-05-15),

Title: Douglas J. Sheffler: Innovator in Metabotropic Glutamate Receptor Modulation

Introduction

Douglas J. Sheffler is a prominent inventor based in San Diego, California. He has made significant contributions to the field of pharmacology, particularly in the development of compounds that target metabotropic glutamate receptors. With a total of eight patents to his name, Sheffler's work has the potential to impact various therapeutic areas.

Latest Patents

Among his latest patents, Sheffler has developed metabotropic glutamate receptor negative allosteric modulators (NAMs). These small molecule compounds specifically target metabotropic glutamate subtype-2 and -3 receptors, offering new avenues for treatment. Additionally, he has patented ULK1 inhibitors, which provide methods for treating diseases by co-administering these inhibitors with mTOR inhibitors. These innovations highlight his commitment to advancing medical science.

Career Highlights

Throughout his career, Douglas J. Sheffler has worked with esteemed institutions such as the Sanford Burnham Prebys Medical Discovery Institute and The Salk Institute for Biological Studies. His experience in these research environments has allowed him to collaborate with leading scientists and contribute to groundbreaking research.

Collaborations

Sheffler has collaborated with notable colleagues, including Reuben J. Shaw and Daniel F. Egan. These partnerships have fostered a collaborative spirit in the pursuit of innovative solutions in the field of biological studies.

Conclusion

Douglas J. Sheffler's contributions to the field of pharmacology through his patents and collaborations underscore his role as a key innovator. His work continues to pave the way for advancements in medical treatments and therapies.

This text is generated by artificial intelligence and may not be accurate.